多西紫杉醇联合强的松治疗激素难治性前列腺癌的疗效

目的探讨多西紫杉醇联合强的松治疗激素难治性前列腺癌的临床疗效。方法 64例激素难治性前列腺癌患者随机分为治疗组(32例)和对照组(32例)。两组均每3周(1个治疗周期)用多西紫杉醇75mg/m2静脉滴注1h。治疗组加用强的松5mg,每天2次。比较疗效及不良反应。结果 64例中,5例完成了8个周期治疗,15例6个周期,42例4个周期,2例1个周期。治疗组化疗后总有效率为87.5%,明显高于对照组的56.2%(P<0.05)。治疗组疼痛减轻效果也优于对照组。两组不良反应相仿(P>0.05)。结论多西紫杉醇联合强的松治疗激素难治性前列腺癌疗效确切,明显改善患者生活质量。

Efficacy of combined use of docetaxel and prednisone in treating hormone-refractory prostate cancer

Objective To explore the effect of docetaxel combined with prednisone on hormone-refractory prostate cancer(HRPC).Methods Sixty-four HRPC patients were equally randomized into two groups.The patients in group A were treated with infusion of docetaxel 75 mg/m2 in 1 hour every 3 weeks as one cycle and those in group B were given additional prednisone 5 mg twice a day for 3 weeks.The efficacy and adverse responses were compared.Results Of 64 cases,5 cases completed 8 treatment cycles,25 cases 6 cycles,42 cases 4 cycles and 2 cases 1 cyle.The total effectiveness rate was higher in group A than that in group B(87.5% vs.56.2%)(P<0.05).The decrease of pain score in group A was more than that in group B.There was no significant difference in adverse responses between two groups.Conclusion The docetaxel combined with prednisone is effective in treating HRPC with remarkable improvement of life quality.